Phase III, International, Randomized, Controlled Study of Rigosertib versus Physician’s choice of Treatment in Patients with Myelodysplastic Syndrome after Failure of a Hypomethylating Agent

Type of Cancer
Myelodysplastic Syndrome

Site
Bethesda

Sponsor
Onconova Therapeutics, Inc.

Protocol Number
04-30

To Learn More Call
201-510-0910